Showing results (171-180 of 203) with videos related to
Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factorKatharina Wagner, Frederik Damm, Gudrun Göhring, et al.Cancer Research|July 23, 2013
SOX2 expression associates with stem cell state in human ovarian carcinomaPetra M Bareiss, Anna Paczulla, Hui Wang, et al.Oncoimmunology|April 14, 2017
HLA class I-restricted <i>MYD88</i> L265P-derived peptides as specific targets for lymphoma immunotherapyAnnika Nelde, Juliane Sarah Walz, Daniel Johannes Kowalewski, et al.The Lancet. Oncology|October 26, 2010
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trialEckhard Thiel, Agnieszka Korfel, Peter Martus, et al.Blood|April 28, 2006
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Barbara Wassmann, Heike Pfeifer, Nicola Goekbuget, et al.Nature Communications|October 4, 2017
NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemiaMelanie Märklin, Jonas S Heitmann, Alexander R Fuchs, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Volker Diehl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly TrialHanneke C Kluin-Nelemans, Eva Hoster, Olivier Hermine, et al.Leukemia|February 27, 2018
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saussele, Rüdiger Hehlmann, Alice Fabarius, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I StudyMaria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, et al.Pageof 21